Light Sciences Oncology Appoints David P. Holveck to Its Board of Directors
development of our light-activated drug therapy."
"Joining the lso
board is a great opportunity to help guide this
dynamic company in its futu...ver, the Company has
completed a Phase II clinical trial of Litx in glioma. lso
has widened the
scope of potential therapeutic applications for Litx to inc...